2024
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Pach J, Valido K, Belzer A, Leventhal J. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases. American Journal Of Clinical Dermatology 2024, 25: 595-607. PMID: 38767827, DOI: 10.1007/s40257-024-00866-z.Peer-Reviewed Original ResearchCutaneous immune-related adverse eventsImmune-related adverse eventsAdverse eventsAntitumor responseBiological agentsHigh-dose systemic corticosteroidsSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeCutaneous adverse reactionsAdverse event patternEnglish-language literatureTransient acantholytic dermatosisTreating high-gradeSpectrum of dermatologic manifestationsCheckpoint inhibitorsSystemic corticosteroidsCorticosteroid-sparingImmunobullous disordersPsoriasiform eruptionLichenoid reactionsEczematous dermatitisLichenoid eruptionDermatological manifestationsHigh-gradeSuccessful treatment of pityriasis rubra pilaris with brodalumab after nonresponse to IL-17A inhibition: A role for the innate cytokine IL-17C
Valido K, Murphy M, Leventhal J, Damsky W. Successful treatment of pityriasis rubra pilaris with brodalumab after nonresponse to IL-17A inhibition: A role for the innate cytokine IL-17C. JAAD Case Reports 2024, 48: 85-87. PMID: 38783931, PMCID: PMC11111584, DOI: 10.1016/j.jdcr.2024.04.010.Peer-Reviewed Original ResearchImmune Checkpoint Inhibitor-Induced Psoriasis Diagnosis, Management, and a Review of Cases
Pach J, Mbonu N, Bhullar S, Cohen J, Leventhal J. Immune Checkpoint Inhibitor-Induced Psoriasis Diagnosis, Management, and a Review of Cases. Dermatologic Clinics 2024, 42: 481-493. PMID: 38796277, DOI: 10.1016/j.det.2024.02.012.Peer-Reviewed Original ResearchThe Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
Belzer A, Pach J, Valido K, Leventhal J. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature. American Journal Of Clinical Dermatology 2024, 25: 435-445. PMID: 38366030, DOI: 10.1007/s40257-024-00847-2.Peer-Reviewed Original ResearchDermatologic adverse eventsAdverse eventsQuality of lifeManagement of dermatologic adverse eventsDiscontinuation of treatmentDermatology Life Quality IndexQuality of life of oncological patientsLife Quality IndexRadiation therapyCytotoxic chemotherapyDose reductionOral mucosaTargeted therapyOncological therapyProphylactic treatmentDrug classesEarly managementOncology patientsPatientsQuality-of-life concernsLife-prolonging treatmentTherapyPatient well-beingDeclining quality of lifeImpact patientsMulti-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors
Bang A, Fay C, LeBoeuf N, Etaee F, Leventhal J, Sibaud V, Arbesman J, Wang J, Kwong B. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Research And Treatment 2024, 204: 643-647. PMID: 38224427, DOI: 10.1007/s10549-023-07217-2.Peer-Reviewed Original ResearchVitiligo-like lesionsProgression-free survivalSurvival benefitMedian progression-free survivalAssociated with survival benefitSkin-directed therapiesMetastatic breast cancerSun-exposed areasPotential treatment optionCyclin-dependent kinase 4ConclusionClinical characteristicsMild repigmentationRuxolitinib creamTopical ruxolitinibMethodsRetrospective reviewResultsMedian ageClinical characteristicsCase reportTreatment optionsBreast cancerKinase inhibitorsCDK4/6iInternational cohortPatientsQuality of life
2023
Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology service
Pach J, Nelson C, Leventhal J. Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology service. JAAD International 2023, 15: 21-23. PMID: 38371669, PMCID: PMC10869938, DOI: 10.1016/j.jdin.2023.11.011.Peer-Reviewed Original ResearchTargeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.Peer-Reviewed Original Research44291 Population-level data reveals prognostic factors and contextualizes outcomes of malignant blue nevus
Mirza F, Yumeen S, Mirza H, Zogg C, Leventhal J, Cohen J. 44291 Population-level data reveals prognostic factors and contextualizes outcomes of malignant blue nevus. Journal Of The American Academy Of Dermatology 2023, 89: ab208. DOI: 10.1016/j.jaad.2023.07.835.Peer-Reviewed Original ResearchPersistent oral ulcers in a woman with thymoma
Lockwood N, Bhullar S, Panse G, Leventhal J. Persistent oral ulcers in a woman with thymoma. JAAD Case Reports 2023, 41: 40-43. PMID: 37842161, PMCID: PMC10568229, DOI: 10.1016/j.jdcr.2023.08.015.Peer-Reviewed Original ResearchRecognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut
Dowton A, Doernberg M, Heiman E, Barelli P, Golden M, Wang H, Leventhal J, Morford K, Sue K. Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut. Journal Of Addiction Medicine 2023, 17: 739-741. PMID: 37934550, DOI: 10.1097/adm.0000000000001198.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersDrug useCase report presentsIndex of suspicionInjection drug useDrug supplyCare management strategiesHarm reduction strategiesOverdose presentationsCutaneous manifestationsWithdrawal syndromeClinical complicationsCase reportIntravenous useWound carePatientsTreatment of woundsInfectious diseasesChronic woundsXylazineSkin woundsWoundsMore reportingDiagnosisPseudocellulitis in oncology patients: A single institutional retrospective analysis investigating the clinical presentation, therapeutic response, and implications for cancer therapy
Pach J, Nelson C, Leventhal J. Pseudocellulitis in oncology patients: A single institutional retrospective analysis investigating the clinical presentation, therapeutic response, and implications for cancer therapy. JAAD International 2023, 12: 186-188. PMID: 37560470, PMCID: PMC10407291, DOI: 10.1016/j.jdin.2023.04.016.Peer-Reviewed Original ResearchPD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens
Damo M, Hornick N, Venkat A, William I, Clulo K, Venkatesan S, He J, Fagerberg E, Loza J, Kwok D, Tal A, Buck J, Cui C, Singh J, Damsky W, Leventhal J, Krishnaswamy S, Joshi N. PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens. Nature 2023, 619: 151-159. PMID: 37344588, PMCID: PMC10989189, DOI: 10.1038/s41586-023-06217-y.Peer-Reviewed Original ResearchConceptsEffector CD8 T cellsCD8 T cellsAntigen-specific effector CD8 T cellsAntigen-specific CD8 T cellsAntigen-expressing cellsT cell tolerancePD-1T cellsAdverse eventsCell toleranceCD8 T cell toleranceImmune-related adverse eventsPeripheral T cell repertoirePeripheral T cell toleranceNon-lesional skinT cell repertoireT-cell antigensPeripheral toleranceCheckpoint receptorsSkin biopsiesLocal infiltrationLocal pathologyCell repertoireMouse modelSkin toleranceMalignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database
Yumeen S, Mirza F, Mirza H, Zogg C, Leventhal J, Cohen J. Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database. Journal Of The American Academy Of Dermatology 2023, 89: 843-846. PMID: 37343827, DOI: 10.1016/j.jaad.2023.05.090.Peer-Reviewed Original ResearchImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearanceCrusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis.
Olamiju B, Leventhal J, Vesely M. Crusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis. Cutis 2023, 111: e44-e47. PMID: 37406327, DOI: 10.12788/cutis.0794.Peer-Reviewed Original ResearchConceptsCrusted scabiesMedication-induced immunosuppressionTreatment of granulomatosisBone marrow transplantationDiagnosis of scabiesVar hominisIatrogenic immunosuppressionBroad differentialMarrow transplantationAutoimmune diseasesSolid organsRare caseSevere formPatientsImmunosuppressionErythrodermaScabiesInfectionEctoparasitic infectionsPolyangiitisGranulomatosisTreatmentMyelosuppressionTransplantationDiseaseTreatment of persistent erythema multiforme with upadacitinib: A novel therapeutic approach
Deutsch A, Rodriguez N, Roy S, Leventhal J. Treatment of persistent erythema multiforme with upadacitinib: A novel therapeutic approach. JAAD Case Reports 2023, 34: 70-73. PMID: 37013105, PMCID: PMC10066506, DOI: 10.1016/j.jdcr.2023.02.010.Peer-Reviewed Original ResearchDermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer
Ahmad M, Saeed S, Olamiju B, Silber A, Leventhal J. Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer. International Journal Of Women's Dermatology 2023, 9: e073. PMID: 36733315, PMCID: PMC9886509, DOI: 10.1097/jw9.0000000000000073.Peer-Reviewed Original ResearchDermatologic toxicitiesSOC patientsBreast cancerEducational interventionFurther multi-institutional studiesCancer treatmentMulti-institutional studyAfrican American/BlackDermatologic effectsInfusion centerAmerican/BlackPatient educationMinority patientsColor patientsEducational pamphletChemotherapyPatientsLarger sample sizeMedical careSkin typePilot studyHigh school degreeSmall sample sizeSample sizeMost participantsA rare case of viral-associated trichodysplasia spinulosa in a patient with chronic lymphocytic leukemia
Choi R, Bhullar S, McNiff J, Persico J, Leventhal J. A rare case of viral-associated trichodysplasia spinulosa in a patient with chronic lymphocytic leukemia. International Journal Of Women's Dermatology 2023, 9: e069. PMID: 36846188, PMCID: PMC9949812, DOI: 10.1097/jw9.0000000000000069.Peer-Reviewed Original ResearchEvaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability
Belzer A, Pach J, Mortlock R, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal J. Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability. JAAD International 2023, 11: 174-175. PMID: 37252181, PMCID: PMC10213716, DOI: 10.1016/j.jdin.2023.02.007.Peer-Reviewed Original ResearchFactors associated with the use of adjuvant radiation therapy in stage III melanoma
King A, Lee V, Yu B, Mirza F, Zogg C, Yang D, Tran T, Leventhal J, An Y. Factors associated with the use of adjuvant radiation therapy in stage III melanoma. Frontiers In Oncology 2023, 13: 1005930. PMID: 36816935, PMCID: PMC9929351, DOI: 10.3389/fonc.2023.1005930.Peer-Reviewed Original ResearchAdjuvant radiation therapyStage III melanomaNational Cancer Data BaseRadiation therapyPositive nodesNational Comprehensive Cancer Network guidelinesUse of RTUtilization of RTMultivariable logistic regression analysisPalliative intent therapyDistant metastatic diseasePrimary treatment modalityMajority of patientsMicroscopic residual tumorHospital-specific factorsMultivariable regression analysisLogistic regression analysisRegression analysisMetastatic diseaseOverall cohortResidual tumorDisease benefitNetwork guidelinesPalliative careMean age